CurrentBlue Cross Blue Shield - IowaPolicy 05.01.85

Esbriet (pirfenidone) — Drug Coverage for Idiopathic Pulmonary Fibrosis

Defines prior authorization, documentation, quantity limits, and medical necessity criteria for Esbriet (pirfenidone) for members with idiopathic pulmonary fibrosis (IPF) under Wellmark/Blue Cross Blue Shield - Iowa.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyEsbriet (pirfenidone) — Drug Coverage for Idiopathic Pulmonary Fibrosis

Policy CodePolicy 05.01.85

Change TypeNo material change

Effective Date

Next Review DateApr 1, 2025

Key ActionObtain prior authorization with submission of chest HRCT (and biopsy report if available) and required diagnostic documentation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization period

9/dayQL 267 mg

3/dayQL 801 mg

FDA-approvedindication

Coverage and Medical Necessity Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

IPF diagnosis and exclusions: Member has idiopathic pulmonary fibrosis and other known causes of interstitial lung disease (e.g., domestic and occupational environmental exposures, connective tissue disease, drug toxicity) have been excluded.

Authorization of 12 months may be granted when diagnostic work-up is complete.

Diagnostic imaging or pathology: Member has completed a high-resolution computed tomography (HRCT) study of the chest with results consistent with usual interstitial pneumonia (UIP) pattern OR has HRCT showing probable/indeterminate UIP supported by lung biopsy showing UIP.

If lung biopsy not performed, diagnosis must be supported by multidisciplinary discussion between an experienced radiologist and pulmonologist.

Continuation Therapy

Covered when ALL of the following are met

Current therapy: Member is currently receiving Esbriet (pirfenidone) (excluding when obtained only as samples or via manufacturer patient assistance programs).

Authorization may be granted for 12 months.

Drug Formulations, Dosing, and Quantity Limits

Drug formulations and quantity limitsNDCCovered

267 mg	Esbriet (pirfenidone) 267 mg tablets — quantity limit 9 per day
801 mg	Esbriet (pirfenidone) 801 mg tablets — quantity limit 3 per day

Esbriet (pirfenidone) dosing — FDA-recommended escalation

Titration days 1-7267 mg three times daily (total 801 mg/day)

Titration days 8-14534 mg three times daily (total 1,602 mg/day)

Maintenance dosing801 mg three times daily (total 2,403 mg/day)

Tablet formulations and quantity limits267 mg tablets: quantity limit 9 per day; 801 mg tablets: quantity limit 3 per day

Prior Authorization, Documentation, and Approval Details

Prior Authorization

Prior Authorization Required

Prior authorization is required before initiation of Esbriet (pirfenidone). Authorization may be granted for up to 12 months when required documentation is submitted and criteria are met.

Prior authorization required for initial and continuation therapy
Authorization duration: up to 12 months

Note

Providers must submit clinical documentation to support the diagnosis and medical necessity of Esbriet. This is a reminder of provider responsibilities for prior authorization submissions and follow-up.

Documentation Required

Required Diagnostic Documentation

Required diagnostic documentation for initial approval includes HRCT results and, when available, lung biopsy pathology and related diagnostic work-up demonstrating idiopathic pulmonary fibrosis (IPF). If a lung biopsy was not performed, documentation of a multidisciplinary discussion between an experienced radiologist and pulmonologist supporting the diagnosis is required. Also include documentation that other known causes of interstitial lung disease have been excluded.

Chest high-resolution computed tomography (HRCT) results
Lung biopsy pathology report, if a biopsy was performed
If no biopsy, documentation of multidisciplinary discussion between radiologist and pulmonologist experienced in IPF
Documentation that other known causes of interstitial lung disease have been excluded (environmental exposures, connective tissue disease, drug toxicity, etc.)

Denial Risk

Denial Risk — Criteria Not Met

Esbriet (pirfenidone) is considered not medically necessary and will be denied when the patient does not meet the documented diagnostic and prior authorization criteria described above.

Background and Indication

Pirfenidone (Esbriet) is an antifibrotic agent indicated for the treatment of idiopathic pulmonary fibrosis (IPF). Diagnosis of IPF requires exclusion of other known causes of interstitial lung disease and supportive diagnostic evaluation (for example, high-resolution computed tomography or lung biopsy). When members do not meet the required diagnostic and documentation criteria, treatment with Esbriet is considered not medically necessary.

Key Definitions and Diagnostic Work-up

Usual interstitial pneumonia (UIP) pattern — supportive findings for IPF

Definition of UIP supporting IPFHRCT or lung biopsy result consistent with the usual interstitial pneumonia (UIP) pattern

Probable/indeterminate UIP on HRCTHRCT showing probable or indeterminate UIP can support IPF diagnosis only when lung biopsy shows UIP

When biopsy absentIf lung biopsy was not performed, diagnosis must be supported by multidisciplinary discussion between an experienced radiologist and pulmonologist

Diagnostic work-up for IPF — required documentation

Required imagingHigh-resolution computed tomography (HRCT) of the chest must be completed and submitted

Pathology when availableIf a lung biopsy is conducted, the associated pathology report must be submitted

Exclusion of other causesOther known causes of interstitial lung disease (e.g., environmental exposures, connective tissue disease, drug toxicity) must be excluded

Multidisciplinary confirmationIf HRCT shows non-UIP patterns and no biopsy was done, a multidisciplinary discussion between an experienced radiologist and pulmonologist supporting the IPF diagnosis is required